

Distinct Patterns of Cleavage and Translocation of Cell Cycle Control Proteins in CD95-induced and p53-induced apoptosis

Apoptotic cell death induced by p53 occurs at a late G1 cell cycle checkpoint termed the restriction (R) point, and it has been proposed that p53-induced apoptosis causes upregulation of CD95. However, as cells with defective in CD95 signaling pathway are still sensitive to p53-induced apoptosis, CD95 cannot be the sole factor resulting in apoptosis. In addition, unlike p53-induced apoptosis, the relationship between CD95-mediated apoptosis and the cell cycle is not clearly understood. It would therefore be worth investigating whether CD95-mediated cell death is pertinent with p53-induced apoptosis in view of cell cycle related molecules. In this report, biochemical analysis showed that etoposide-induced apoptosis caused the induction and the nuclear translocation of effector molecules involved in G1 cell cycle checkpoint. However, there was no such translocation in the case of CD95-mediated death. Thus, although both types of apoptosis involved caspase activation, the cell cycle related proteins responded differently. This argues against the idea that p53-induced apoptosis occurs through the induction of CD95/CD95L expression.

Key Words : *Etoposide; Cell Cycle; Nuclear Translocation; Caspase; DNA Damage; Apoptosis*

Weon Seo Park, Kyeong Cheon Jung^{*},
Doo Hyun Chung^{*}, Woo-Dong Nam[†],
Won Jin Choi[†], Youngmee Bae

Department of Pathology, [†]Orthopaedic Surgery, and ^{*}General Surgery, Kangwon National University College of Medicine, and Clinical Research Institute of Kangwon National University Hospital, Chuncheon; [‡]Department of Pathology, Hallym University College of Medicine, Chuncheon; ^{*}Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

Received : 20 February 2003

Accepted : 18 March 2003

Address for correspondence

Youngmee Bae, D.Phil.
Department of Pathology, Kangwon National University College of Medicine, 192-1 Hyoja-dong, Chuncheon 200-701, Korea
Tel : +82.33-250-8844, Fax : +82.33-242-7571
E-mail : ymbae@kangwon.ac.kr

*This work was supported by grant (R11-2002-098-00000-0) from Korea Science & Engineering Foundation through the RRC (Rheumatism Research Center) at Catholic University, and a Korea Research Foundation Grant (2000-042-F00017).

INTRODUCTION

All somatic cells proliferate using common mechanism of mitosis following progression through the cell cycle. In addition, apoptosis or programmed cell death appears to be a ubiquitous process in multicellular organisms to remove unwanted or damaged cells (1, 2). As it is essential to identify and eliminate cells proliferating inappropriately, apoptosis and proliferation are tightly coupled, and cell cycle regulators can influence both cell division and cell death (1). It is well understood that cell cycle checkpoints monitor the timing and order of cell cycle events, and these occur at the G1/S phase boundary, in S phase, and during the G2 and M phases (2). These checkpoints ensure that important events in each phase of the cell cycle are completed before a new phase is initiated, thereby preventing the formation of genetically abnormal cells. During G1, the cell decides whether to continue through the cell cycle and divide, or leave the cell cycle and enter a state of quiescence (G0). Pardee further introduced the term restriction (R) to define the point in G1, after which cells can prolifer-

ate independent of mitogenic stimuli, and also suggested the importance of the R point in malignant transformation (3).

Proteins, which are involved in the G1 checkpoint include p53, pRb, and the E2F family of transcription factors (4). The p53 protein is thought to be an essential mediator that regulates the R point (5). The p53 protein is induced by DNA damaging chemicals as well as by ionizing radiation. p53 is required for G1 arrest and/or apoptosis following DNA damage (6). p53 activates the transcription of several genes and the best studied target molecule is p21^{WAF1/Cip1}, which has a role in p53-mediated G1 arrest (2). In addition, the expression of the proapoptotic gene, *bax*, is upregulated by p53 induced after DNA damage, and this upregulation causes apoptosis (7). p53 induces apoptosis as well as G1 arrest, but G1 arrest is not a prerequisite for p53 induced apoptosis. Cells from p21^{WAF1/Cip1} (-/-) mice, for example, exhibit a defect in p53 induced G1 arrest, but show normal p53-mediated apoptosis (8). Therefore, p53 induction may cause G1 arrest or apoptosis, depending on the cell type.

Cells are able to undergo apoptosis in response to various

stimuli (2, 4), including death receptor ligation, cytotoxic drugs, ionizing radiation, and DNA damaging chemicals. Among receptors that induce apoptosis, CD95 (Apo-1 or Fas) is a member of the TNF receptor family, and is expressed on various types of cells including thymocytes (9) and activated T cells (10, 11). When CD95 interacts with its ligand (CD95L), CD95 is trimerized and the trimer recruits an adaptor protein Fas associated death domain (FADD), which in turn activates caspase 8. This upstream or initiator caspase has two death effector domains (DED) at its N-terminus (12). This leads to the activation of other caspases, resulting in the cleavage of multiple vital substrates and apoptosis (13). Many studies have been focused on CD95-mediated death, but its relationship with the cell cycle is still controversial. For instance, Dao *et al.* reported that CD95-mediated death happens in G1 phase suggesting that CD95-mediated death may mimic death at the R point, while Boehme and Lenardo suggested that activation induced cell death (AICD) of T cells occurs in S phase (14, 15).

It has been shown that p53 activation induces CD95 and/or its ligand through a translation-independent pathway (16) and transiently sensitizes cells to CD95-induced apoptosis (16). However, this cannot be a general mechanism as etoposide-induced apoptosis can be CD95-independent (17, 18). For example, cells without FADD or that express a dominant-negative FADD, and which are therefore defective in CD95 signaling, are still sensitive to ionizing radiation and DNA-damaging chemicals (19, 20). Furthermore, Chen and Tan reported that induction of CD95 expression alone was not sufficient to induce apoptosis in irradiated cells (18). Thus, the relationship between CD95-induced and R checkpoint-based apoptotic mechanisms needs to be understood. These findings prompted us to compare the biochemical basis of p53-induced and CD95-induced apoptosis in T cells, with respect to cell cycle control proteins.

Etoposide was used in this study to induce apoptosis, as it is known to inhibit topoisomerase II and cause DNA double strand breaks, which result in apoptosis mediated through p53 induction (21). We chose Jurkat cells as target cells to induce apoptosis as they are known to be sensitive to both CD95 and etoposide mediated apoptosis (22). Thus, we have studied the possible convergence of caspase-based and cell cycle checkpoint-based apoptotic mechanisms in response to two stimuli, CD95 ligation and etoposide treatment. We reasoned that, if a CD95-based mechanism were the principal downstream effector of p53 induction, both etoposide-induced and CD95-induced apoptosis would result in similar patterns of substrate changes. However, the patterns we observed were quite different. We found that DNA damage induced p53 and showed strong mobilization of cell cycle R checkpoint-associated proteins to the cell nucleus, while no such movements were seen in CD95-mediated apoptosis. This argues against the idea that p53-induced apoptosis occurs through the induction of CD95/CD95L expression.

MATERIALS AND METHODS

Cells and Reagents

Jurkat cells were maintained in RPMI1640 containing 10% fetal calf serum (FCS, Hyclone Logan, UT, U.S.A.), 2 mM L-glutamine, 50 μ M β -mercaptoethanol, 10 mM HEPES, and 100 U/mL each of penicillin and streptomycin. Polyclonal or monoclonal antibodies against a number of cell cycle control proteins were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). They were anti-p53 (sc-126), anti-E2F-1 (sc-193), anti-E2F-4 (sc-866), anti-p21^{WAF1/Cip1} (sc-397), anti-p27^{Kip1} (sc-776), anti-CDK4 (sc-601), anti-p107 (sc-250), and anti-pRb (sc-50) antibodies. Anti-mouse or anti-rabbit Ig anti-serums coupled to horseradish peroxidase (HRP) were also from Santa Cruz Biotechnology. Etoposide was purchased from Sigma (St. Louis, MO, U.S.A.). The caspase inhibitors, z-VAD-fmk and DEVD-CHO, were from Calbiochem (La Jolla, CA, U.S.A.).

Cell Culture and Flow Cytometric Analysis

Jurkat cells were suspended at 0.5×10^6 cells/mL in a final volume of 10 mL of RPMI culture medium, and layered over control or CD95L-expressing fibroblasts (14) in 10 cm dishes (Falcon 35-3003, Becton-Dickinson, Franklin Lakes, NJ, U.S.A.). At the indicated time points, non-adherent Jurkat cells were harvested and then tested for apoptosis (using PI staining to detect sub-diploid cells) or lysed for western blot analysis. To detect sub-diploid cells, a suspension of cells were incubated with propidium iodide (PI) at 50 μ g/mL (Sigma Chemical Co.) for 30 min in 0.1% sodium citrate, 0.3% Nonidet P-40, and 50 μ g/mL RNase. PI stained cells were analyzed using a FACScalibur (Becton-Dickinson, Mountain View, CA, U.S.A.) and data were analyzed using Cellquest software.

Immunoblotting Analysis

Jurkat cells were centrifuged and then the cell pellet was washed and lysed in the Laemmli buffer containing a protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany). In order to separate cytoplasmic and nuclear proteins, Jurkat T cells were incubated with CD95L expressing fibroblasts, or treated with 50 μ M of etoposide, and subcellular fractionation was performed as described previously (23). Briefly, cells were lysed in a hypotonic buffer (10 mM HEPES-KOH, pH 7.9; 10 mM KCl; 1.5 mM MgCl₂; 0.5 mM dithiothreitol) containing 0.1% Triton X-100, and fractionated by low speed centrifugation into a low-salt-soluble supernatant for cytoplasmic proteins and an insoluble nuclear pellet. The insoluble nuclear pellet fraction was extracted further with ELB (50 mM HEPES, pH 7.2; 250 mM NaCl; 2 mM EDTA; 0.1% NP-40). The protein concentration was checked by using BioRad solution (Bio-Rad DC Protein Assay Kit I, BioRad) and the same

amount of proteins were loaded onto 6, 10, 12, or 15% SDS-PAGE gels, electrophoresed, and transferred to PVDF Immobilon membranes (Millipore, Bedford, MA, U.S.A.) using an electrotransfer apparatus from Bio-Rad (Hercules, CA, U.S.A.).

Transferred membranes were incubated with primary antibodies recognizing each of the cell cycle related proteins for 1-3 hr at room temperature, followed by extensive washing. Immune complexes were tagged using goat anti-rabbit or rabbit anti-mouse HRP, then visualized using the enhanced chemiluminescent (ECL) kit from Amersham Life Sciences (Buckinghamshire, U.K.).

RESULTS

In order to determine the role of caspases in CD95 or etoposide-mediated apoptosis in Jurkat cells, the pan-caspase inhibitor, z-VAD-fmk was added to cells subjected to either of two death signals: CD95-engagement or etoposide treatment. CD95 is known to activate caspase 8 through interaction of its death domain with FADD while etoposide, a DNA damaging agent, causes p53-induced cell death. In both cases, Jurkat cells underwent apoptosis which was verified by PI staining (Fig. 1). Upon CD95 ligation, Jurkat cells responded rapidly as ~52% cells were subdiploid after the 5 hr incubation with CD95L expressing fibroblasts. Etoposide induced cell death was as extensive as that of CD95 ligation but it took 18 hr to cause the same percentage of apoptotic cells (Fig. 2). In order




Fig. 1. Apoptosis induced by CD95 ligation or etoposide treatment in Jurkat cells. 50 μ M etoposide or co-culture of CD95L expressing fibroblasts was applied to induce apoptosis as described in Material and Methods. 10-150 μ M of z-VAD-fmk or same volume of DMSO (control) was added to block the caspase activation. After 8 hr incubation, the degree of apoptosis was determined by counting subdiploid cells by using a PI staining and analyzed by FAC-Scalibur. open circle, Jurkat cells co-cultured with control fibroblasts (vector 3T3 cells); closed circle, co-cultured with CD95L transfected fibroblasts; open square, cultured in media containing DMSO; and closed square, culture with 50 μ M of etoposide.

to examine whether caspases were the mediators of apoptosis in both cases, the caspase-inhibitor, z-VAD-fmk, was added at various concentrations. As shown in Fig. 1, z-VAD-fmk was able to block apoptosis in both cases. However, CD95-induced apoptosis was more sensitive to z-VAD-fmk inhibition, since even 10 μ M z-VAD-fmk caused significant blockade of CD95-induced Jurkat cell death, while significant blockade of etoposide-induced death required 40 μ M z-VAD-fmk.

In the case of CD95 mediated death, z-VAD-fmk blocks the caspase 8 pathway and the subsequent cascade of caspase activation. In etoposide treatment, it is known that p53 induc-




Fig. 2. The expression of cell cycle related proteins upon treatment with apoptotic stimuli. For etoposide-induced apoptosis, Jurkat cells were incubated in media containing 50 μ M etoposide for 18 hr. Media alone was used as a control. To induce CD95 mediated death, Jurkat cells were co-cultured with CD95L-transfected fibroblasts or control fibroblasts (vector-3T3). Apoptotic cells were calculated by counting subdiploid cells using PI staining as described in Material and Methods. In order to block caspase action, caspase inhibitors, 50 μ M of either z-VAD-fmk or DEVD-CHO was added before the induction of apoptosis. 30 μ g of protein extracts from each sample was subjected to SDS-PAGE. The arrows indicate each cell cycle protein. Overexposure of the p53 blot was used to verify the induction of p53 in CD95-mediated apoptosis. p107 has a caspase recognition site producing a 15 kDa C-terminal fragment which is recognized by anti-p107 ab (sc-250) and is indeed visualized by immunoblotting (p107 fragments).




Fig. 3. Nuclear translocation of G1 cell cycle proteins. Etoposide and CD95 ligation were applied as described in Fig. 2. At the indicated time point, Jurkat cells were pelleted and cytoplasm and nuclear proteins were fractionated as described in Material and Methods. 30 μ g of each sample (either cytoplasm or nuclei) were separated and immunoblotting was performed with the antibodies indicated. C: cytoplasmic extracts, N: nuclear extracts. Arrows indicate each cell cycle protein and arrowheads in the p27^{Kip-1} blot are believed to indicate caspase-cleaved fragments.

tion leads to bax expression that activates apoptosis (24).

In addition, it was reported that the expression of CD95/CD95L was upregulated by p53 induced by DNA damaging agents (16). However, it is controversial whether p53-mediated death occurs through CD95-upregulation followed by its engagement by simultaneously up-regulated CD95L. Furthermore, it is not known at which phase of the cycle cells become targets for CD95 mediated apoptosis, nor how cell cycle-related molecules would respond during apoptosis due to CD95 ligation in T cells. In the case of p53-mediated death, it is well documented that apoptosis occurs at the R point which is G1/S boundary (2). We reasoned that, if a CD95-based mechanism were the principal downstream effector of p53 induction, both etoposide induced and CD95-induced apoptosis would result in similar pattern of substrate cleavage. In view of the controversy surrounding the relationship between apoptosis and cell cycle control, we focused on the cell cycle proteins that regulate G1 phase. These include p53, E2F-4, the cyclin-dependent kinase inhibitors, p21^{WAF1/Cip1} and p27^{Kip-1}, and the pocket protein, p107.

Fig. 2 shows the expression of these molecules in response

to CD95 ligation or treatment with etoposide. As expected, strong induction of p53 was found in etoposide-treated cells, while very little induction was seen in CD95 mediated death even when a longer exposure time was used. This finding confirmed that etoposide induces classic p53-mediated apoptosis. Furthermore, p21^{WAF1/Cip1} was induced in both CD95 and etoposide mediated death, although the amount induced was much higher in the case of etoposide treatment. This is also thought to be p53 dependent. For p27^{Kip-1}, both stimuli led to the degradation of this protein. This could be caused by ubiquitination, or through caspase activity. In fact, it was shown that p27^{Kip-1} is rapidly ubiquitinated during the G1-S transition (25). However, it was recently reported that p27^{Kip-1} is cleaved by caspase action, and that this resulted in increased cell death in human epithelial cells (26). In Jurkat cells, caspase-mediated breakdown of p27^{Kip-1} also appeared to be important, since the loss of p27^{Kip-1} was inhibited by z-VAD-fmk.

The E2F family consists of 6 members, which act as transcription factors. They are believed to be critically positive regulators of cell cycle progression. Among them, E2F-1 either induces or protects cells from apoptosis, depending on the cell type and the apoptotic stimuli (27, 28). Although E2F-4 is expressed in the early phases of the cell cycle and the expression continues throughout the cycle (29), the role of E2F-4 in apoptosis is poorly understood. We were only able to detect only trace amounts of E2F-1 in Jurkat cells, but E2F-4 was abundant (Fig. 3). We therefore focused on the expression of E2F-4, which might regulate G1 progression. In the experiment shown in Fig. 2, there was not much difference in the expression of E2F-4, although the density of the hyperphosphorylated form of the protein was slightly reduced. This was possibly a result of cleavage by caspases, as there is a conserved caspase-3 cleavage site at the C-terminus in all E2F family members.

DISCUSSION

The pocket proteins are the partners of E2Fs. The retinoblastoma protein pRb interacts with E2F-1 to inhibit the function of E2F-1 from acting as a transcription factor, while the pRb-related proteins, p107 and p130, bind to E2F-4. Therefore, E2F-4 is thought to play a role in the transition from the G0 to the G1 phase. As both CD95 and etoposide induce apoptosis in G1 phase cells (2, 6, 13, 14, 30), we hypothesized that E2F-4 could be involved in both apoptotic stimuli. Consequently, p130 and/or p107 could be involved in both cases. However, p130 is known to act on the G0-G1 transition, while our main focus of interest is the G1/S transition. We therefore evaluated the expression and modulation of p107. All pocket proteins have caspase-3 target sites, i.e., the DxxD motif, and it is already known that pRb is cleaved during TNFR1 and CD95-mediated apoptosis (31). As shown in Fig. 2, a 15 kDa C-terminal cleavage product of p107 was detected

during apoptosis due to either CD95 ligation or treatment with etoposide. This seemed to be produced by caspase activity, as in CD95-ligated cells the cleavage was completely inhibited by z-VAD-fmk. This is the first demonstration that, in addition to pRb, p107 is one of the substrates of caspase(s) activated upon CD95 ligation.

There were subtle differences between CD95-induced and etoposide mediated apoptosis in Jurkat T cells (Fig. 2). One noteworthy detail was that the breakdown of p107 was inhibited completely by 50 μ M z-VAD-fmk in the case of CD95-induced apoptosis, but only inhibited partially by the same concentration of z-VAD-fmk in etoposide mediated apoptosis. This is a hint that a different spectrum of caspases might be involved in the two different types of apoptosis.

The biological activity of cell cycle control proteins at the G1/S checkpoint is associated with their translocation into the nucleus (1, 5). To test whether this mechanism was operating in Jurkat cells undergoing apoptosis, we examined nuclear vs. cytoplasmic lysates of Jurkat cells during CD95-induced and etoposide-induced apoptosis. Fig. 3 showed the differential translocation of several proteins upon etoposide treatment or CD95 ligation. Interestingly, there was no translocation of p27^{Kip-1} into the nucleus although it has a nuclear localization signal. This suggests that other proteins such as cyclin and/or CDK might regulate the intracellular location of p27^{Kip-1}. The E2F-1 protein did not move into the nucleus upon apoptotic signals, and therefore, it was probably not able to act as a transcription factor under these conditions. In accordance with this, the natural interaction partner of E2F-1, pRb, did not move into the nucleus in either case. In addition, pRb disappeared over 8 hr during etoposide mediated cell death. Therefore, the E2F-1/pRb complex was unlikely to be a mediator in either of these apoptotic signals. This is surprising, as E2F-1-induced cell death is thought to be important in T cells (27). E2F-1 deficient mice exhibit a defect in T lymphocyte development leading to an excess of mature T cells due to defective apoptosis in the thymus (27). Furthermore, it was reported that E2F-1 overexpression causes increased S phase and apoptosis (32), while pRb inhibits both processes (4, 33). However, it is possible that the apoptotic activity of E2F-1 is restricted to certain forms of apoptosis that occur in S phase. As CD95 and p53-mediated apoptosis are supposed to occur in G1 phase or during the G1-S transition, cell cycle proteins regulating G1 phase would be more likely to play a role in apoptosis due to these causes. We therefore think that at least in Jurkat cells, E2F-1-mediated cell death is not the same as G1/S checkpoint death.

There is no concrete evidence that specifically implicates E2F-4 in apoptosis. As mentioned above, p107 is expressed and functional in the G1 phase of the cycle (4). Therefore, it would be informative to determine whether there is differential regulation of this molecule in response to the two distinct apoptotic signals. Among the cell cycle control proteins tested, three molecules were differentially translocated in the two

different types of apoptosis: p21^{WAF1/Cip-1}, E2F-4 and p107. Those molecules were translocated to the nucleus in etoposide-induced apoptosis, but not in CD95-induced apoptosis. In the case of etoposide treatment, the translocation of those molecules could be the result of a G1/S checkpoint, induced through p53. In the mouse system, TCR mediated death is thought to happen in late G1 phase (30), although this is controversial (15) and there is evidence that CD95-mediated death also happens in G1 (13, 14). However, at least in Jurkat cells, our data show that there is no movement of the G1 cell cycle proteins during CD95-induced apoptosis. This implies that CD95-mediated death does not involve the same mechanism as apoptosis associated with the G1-checkpoint. While several previous reports document that etoposide treatment induces CD95/CD95L expression, this may not be the general mechanism of etoposide-induced death in most cell types. In support of this argument, the cells from FADD deficient mice are apoptotic in response to DNA damaging agents (19, 20). Also, thymocytes from p53 deficient mice are sensitive to CD95-mediated death (34).

In summary, we compared the response of cell cycle control proteins to two different apoptotic stimuli, CD95 ligation and treatment with etoposide. Although both pathways were mediated by caspases, the translocation of cell cycle control proteins, especially the G1/S checkpoint-associated G1 molecules, was different. Etoposide induced p53 and showed the p53 dependent, G1/S checkpoint-associated pattern of nuclear translocation of E2F-4, p21^{WAF1/Cip-1}, and p107. In contrast, in CD95 mediated death, there was no translocation of G1/S cell cycle proteins. This suggests that CD95 ligation does not involve the G1/S checkpoint cell cycle control proteins to induce cell death. In addition, while p53 induction may result in CD95/CD95L expression in some systems, it is not the main pathway through which p53 induces apoptosis.

REFERENCES

1. Meikrantz W, Schlegel R. *Apoptosis and the cell cycle*. *J Cell Biochem* 1995; 58: 160-74.
2. King KL, Cidlowski JA. *Cell cycle regulation and apoptosis*. *Annu Rev Physiol* 1998; 60: 601-17.
3. Pardee AB. *A restriction point for control of normal animal proliferation*. *Proc Natl Acad Sci USA* 1974; 71: 1286-90.
4. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. *Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis*. *Proc Natl Acad Sci USA* 1995; 92: 5436-40.
5. Zetterberg A, Larsson O, Wiman KG. *What is the restriction point?* *Curr Opin in Cell Biol* 1997; 7: 835-42.
6. Cox LS, Lane DP. *Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage*. *Bioessays* 1995; 17: 501-8.
7. Miyashita T, Reed JC. *Tumor suppressor p53 is a direct transcription-*

- al activator of human bax gene. *Cell* 1995; 80: 293-9.
8. Deng C, Zheng P, Harper JW, Elledge SJ, Leder P. Mice lacking *p21^{cip1/WAF1}* undergo normal development, but are defective in G1 check-point control. *Cell* 1995; 82: 675-84.
 9. Nagata S. Apoptosis by death factor. *Cell* 1997; 88: 355-65.
 10. Crispe IN. Fatal interactions: Fas-induced apoptosis of mature T cells. *Immunity* 1994; 1: 347-9.
 11. Chung DH, Jung KC, Park WS, Lee I-S, Choi WJ, Kim C-J, Park SH, Bae Y. Costimulatory effect of Fas in mouse T lymphocytes. *Mol Cells* 2000; 10: 642-6.
 12. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. *Cell* 1995; 81: 505-12.
 13. Bae Y, Crispe IN. Differential regulation of cell cycle related proteins by CD95 engagement in thymocytes and T cell leukemic cell line, Jurkat. *J Cell Biochem* 2001; 80: 328-38.
 14. Dao T, Huleatt JW, Hingorani R, Crispe IN. Specific resistance of T cells to CD95-induced apoptosis during S phase of the cell cycle. *J Immunol* 1997; 159: 4261-7.
 15. Boehme SA, Lenardo MJ. Proprietary apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. *Eur J Immunol* 1993; 23: 1552-60.
 16. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. *Science* 1998; 282: 290-3.
 17. Fuchs EJ, McKenna KA, Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. *Cancer Res* 1997; 57: 2550-4.
 18. Chen YR, Tan TH. Lack of correlation in JNK activation and p53-dependent Fas expression induced by apoptotic stimuli. *Biochem Biophys Res Comm* 1999; 256: 595-9.
 19. Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD95 (Fas/APO-1). *J Biol Chem* 1997; 272: 25783-6.
 20. Yeh W-C, Pompa JL, McCurrach ME, Shu H-B, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. *Science* 1998; 279: 1954-8.
 21. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to topoisomerase inhibitors. *Anticancer Res* 1998; 18: 2919-32.
 22. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. *Proc Natl Acad Sci USA* 1998; 95: 6785-90.
 23. Hinds P, Tiemann F. Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature-sensitive retinoblastoma protein. *EMBO J* 1998; 17: 1040-52.
 24. Brady HJM, Salomons GS, Bobeldijk RC, Berns AJM. T cells from bax alpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. *EMBO J* 1996; 15: 1221-30.
 25. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M. Down-regulation of p27^{Kip1} by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. *J Biol Chem* 1999; 274: 13886-93.
 26. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R. Cleavage of p21^{Cip1/Waf1} and p27^{Kip1} mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. *Mol Cells* 1998; 1: 553-63.
 27. Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. *Cell* 1996; 85: 549-61.
 28. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. *Genes Dev* 1997; 11: 1853-63.
 29. Sardet C, Vidal M, Cobrinck D, Geng Y, Onufryk C, Chen A, Weinberg RA. E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. *Proc Natl Acad Sci USA* 1995; 92: 2403-7.
 30. Lissy N A, Dyk LFV, Becker-Hapak M, Vocero-Akbani A, Mendler JH, Dowdy SF. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. *Immunity* 1998; 8: 57-65.
 31. Tan X, Wang JYJ. The caspase-Rb connection in cell death. *Trends in Cell Biol* 1998; 8: 116-20.
 32. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F-1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. *Cell Growth Differ* 1998; 9: 113-8.
 33. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. *Genes Dev* 1997; 11: 1840-52.
 34. Li T, Ramirez K, Palacios R. Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. *Cell Growth Differ* 1996; 7: 107-14.